Peptide Schedule
Crystagen4 residuesAEDREach bubble = one amino acid. Size = residue mass. Color = chemical class.Crystagen
Benefits
About Crystagen
Crystagen is a synthetic tripeptide (Glu-Asp-Pro, molecular weight ~345 Da) developed through the Khavinson peptide bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. It was isolated as one of several bioactive fractions from Thymalin, a polypeptide thymus extract that's been approved in Russian clinical practice since 1982. The peptide targets immune system regulation, specifically T-cell and B-cell populations and thymic epithelial cell activity. In preclinical studies using gamma-irradiated rat models, Crystagen preserved the cortex-medulla architectural division of the thymus, maintained thymocyte proliferation, and increased macrophage and mast cell counts. In elderly patients, oral Crystagen administration contributed to normalization of the immunogram in approximately 82% of cases, according to a Russian clinical report. The peptide also promotes heterochromatinization of chromatin in blood lymphocytes from elderly subjects. In vitro, it activates proliferation of human thymic epithelial cells and inhibits proliferation of K-562 human erythromyelosis tumor cells. Most Crystagen research comes from a single research group, and the peptide hasn't undergone independent Western clinical trials.
Who Should Consider Crystagen
- Individuals over 50 experiencing age-related immune decline
- Researchers studying Khavinson bioregulator peptides and thymic immunomodulation
- People interested in oral peptide bioregulators as an alternative to injectable thymic peptides
- Those with recurrent infections seeking immune support under medical supervision
How Crystagen Works
Crystagen belongs to the Khavinson class of ultrashort peptides proposed to regulate gene expression through direct interaction with DNA and chromatin. The peptide's tissue specificity for immune cells appears determined by its Glu-Asp dipeptide core. In the spleen, Crystagen activates B-cell immunity but doesn't affect cellular renewal processes during aging, distinguishing it from related peptides like Vilon (Lys-Glu), which primarily targets T-helper cells. In thymocyte assays, Crystagen influences T-cell differentiation markers, with reported shifts in CD3+ and CD4+ populations and normalization of CD4+/CD8+ ratios. At the epigenetic level, Crystagen promotes heterochromatinization in aged lymphocytes, suggesting it can alter chromatin condensation states.
What to Expect
Course initiation. No outward immune changes expected in this early window.
Short peptides begin influencing gene expression in immune cells. Subtle shifts in immune cell populations may begin, though unlikely to be noticeable without bloodwork.
End of standard course. The 82% immunogram normalization figure was observed after full treatment courses in elderly patients.
The Khavinson theory holds that short peptide effects persist well beyond the dosing period. The off-cycle allows assessment of whether immune improvements are maintained.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Note: Crystagen (Glu-Asp-Pro) is a synthetic tripeptide derived from the Khavinson peptide bioregulator program, designed to mirror immunomodulatory fractions isolated from Thymalin. Typical courses run 10-30 days and are repeated 2-3 times per year. Take capsules 15-20 minutes before meals.
How to Inject Crystagen
Take 1-2 capsules orally, 15-20 minutes before meals, once daily. Standard course duration is 10-30 days, repeated 2-3 times per year. Capsules should be swallowed whole with water.
Cycling Protocol
Standard Khavinson bioregulator protocol: 10-30 day courses repeated 2-3 times per year. A common regimen is 1-2 capsules daily for 30 days, then a 3-6 month break.
Pharmacokinetics
Source: Estimated from ultrashort peptide kinetics; no direct PK studies on Crystagen published.
Loading the interactive decay curve.
Side Effects
No adverse effects directly attributable to Crystagen have been reported in published studies. However, the safety database is small. Theoretically, immune modulation carries a risk of exacerbating autoimmune conditions. Gastrointestinal discomfort is possible with oral peptide products.
Contraindications
- Active autoimmune disease — immune modulation could worsen autoimmune flares
- Organ transplant recipients on immunosuppressive therapy
- Pregnancy or breastfeeding — no reproductive safety data exists
- Known hypersensitivity to any component of the capsule formulation
Drug Interactions
- Immunosuppressants (cyclosporine, tacrolimus) — Crystagen's immune-stimulating effects may counteract immunosuppressive therapy
- Other thymic peptides (Thymosin Alpha 1, Thymalin) — additive immune stimulation is possible
- Checkpoint inhibitors — combined immune activation effects are unstudied
Storage & Stability
Molecular Profile
Related Peptides
References
- Effects of short peptides on thymocyte blast transformation and signal transduction (Khavinson et al., 2002)PubMed 12420072
- Effects of short peptides on lymphocyte chromatin in senile subjects (Khavinson et al., 2004)PubMed 15085253
- Peptide Regulation of Gene Expression: A Systematic Review (2021)PubMed 34834147
- Peptides of pineal gland and thymus prolong human life (Khavinson & Morozov, 2003)PubMed 14523363
- Molecular aspects of immunoprotective activity of peptides in spleen during ageing (2017)PubMed 28976144